23andMe Holding Co. (ME)
NASDAQ (CM) NASDAQ (CM) Primary Summary
23andMe bankruptcy under congressional investigation for customer data
The House Committee on Energy and Commerce sent a letter to 23andMe expressing concern that its genetic data is "at risk of being compromised." The embattled genetic testing company filed for Chapter 11 bankruptcy protection in March, and its assets are up for sale.
US regulators tell 23andMe to protect genetic data
The US Federal Trade Commission (FTC) on Monday warned genetic testing firm 23andMe to honor its promise to protect people's personal information as it navigates bankruptcy.
What users need to know about privacy and data after 23andMe's bankruptcy filing
23andMe, one of the first companies to provide direct-to-consumer genetic testing kits, has filed for bankruptcy. Since its founding in 2006, it has sold over 12 million DNA kits, with high-profile users including Oprah Winfrey and Warren Buffett.
23andMe Holding Co. (ME) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 23andMe Holding Co. ever had a stock split?
23andMe Holding Co. Profile
| Professional Services Industry | Industrials Sector | Joseph Selsavage CEO | NASDAQ (CM) Exchange | 90138Q306 CUSIP |
| US Country | 560 Employees | - Last Dividend | 16 Oct 2024 Last Split | 23 Nov 2020 IPO Date |
Overview
23andMe Holding Co. is renowned for its pioneering efforts in consumer genetics testing, embodying a unique blend of healthcare and biotechnology. Founded in 2006 and based in South San Francisco, California, the company has grown to operate across two vital segments: Consumer & Research Services and Therapeutics. Through its innovative approach, 23andMe leverages genetic data to offer insightful reports on ancestry, health risks, and medication responses, while also making strides in the development of novel therapies aimed at transforming patient care in areas such as oncology, respiratory, and cardiovascular diseases.
Products and Services
- Genetic Reports
This service delivers comprehensive insights into an individual's genetic ancestral origins, personal health risks, carrier status for rare conditions, and how genetics can influence drug responses. It serves as a foundation for personalized healthcare and wellness planning.
- Lemonaid Telehealth Platform
An integral part of the Consumer & Research Services segment, the Lemonaid platform connects users with licensed healthcare professionals for consultations and treatments addressing common conditions. This service underscores 23andMe's commitment to making healthcare more accessible and tailored to individual needs.
- Research Services
23andMe extends its capabilities to offer research services, leveraging the vast genetic data obtained from consenting customers to fuel studies that advance the understanding of human genetics and health. These efforts not only contribute to the scientific community but also refine the company's consumer offerings.
- Drug Development in Therapeutics Segment
The Therapeutics segment is dedicated to the discovery and development of innovative drugs. It emphasizes patient-centric solutions across several therapeutic areas, including oncology, respiratory diseases, and cardiovascular conditions. By harnessing genetic insights, 23andMe aims to revolutionize the approach to disease treatment and prevention.
- 23ME-00610 (P006)
This humanized monoclonal antibody, currently in phase 1/2a clinical trials, targets the interaction between CD200R1 and CD200 in cancer cells. It represents 23andMe's commitment to developing treatments that directly interfere with cancer cell mechanisms, showcasing the potential of genetics-based therapeutics.
- GSK6097608
An antibody that zeroes in on CD96, aiming to enhance T and NK cell anti-tumor immune responses. This product is a testament to the company's efforts to develop therapies that harness the body's immune system to fight cancer more effectively.
Contact Information
